Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1626 1639 1675 1692
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18236462 | METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASES | Non-Final OA | Genzyme Corporation |
| 18173735 | METHODS AND SYSTEMS FOR PERFORMING SINGLE CELL ANALYSIS OF MOLECULES AND MOLECULAR COMPLEXES | Non-Final OA | CALIFORNIA INSTITUTE OF TECHNOLOGY |
| 18261182 | PROCESS FOR PRODUCTION OF INTERMEDIATES | Final Rejection | DSM IP Assets B.V. |
| 17916843 | Synthesis of vinylic alcohol intermediates | Non-Final OA | AMGEN INC. |
| 18318947 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18258711 | CRYSTALLINE FORM I OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME | Final Rejection | LG CHEM, LTD. |
| 17653897 | FEATURIZATION OF CARBON DIOXIDE CAPTURE CHARACTERISTICS IN MOLECULES | Final Rejection | INTERNATIONAL BUSINESS MACHINES CORPORATION |
| 19190210 | METHODS FOR THE TREATMENT OF BIOLOGICAL AGING | Final Rejection | BIOVIE INC. |
| 17764073 | Method for Treatment of Alzheimer's Disease | Non-Final OA | University of Kentucky Research Foundation |
| 18455152 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | Non-Final OA | University of Washington |
| 18188504 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | Final Rejection | University of Washington |
| 18001832 | TREATMENT OF VIRAL INFECTIONS WITH ESTROGEN RECEPTOR MODULATORS AND ANTI-INFLAMMATORY AGENTS | Final Rejection | THE CLEVELAND CLINIC FOUNDATION |
| 18566394 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18286510 | Combination Comprising Ribociclib and Amcenestrant | Non-Final OA | Sanofi |
| 18058216 | METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING | Final Rejection | Becton, Dickinson and Company |
| 17927642 | Gasdermin D (GSDMD) Succination for the Treatment of Inflammatory Disease | Final Rejection | University of Massachusetts |
| 18556969 | METHODS FOR TREATING SYMPTOMS OF KABUKI SYNDROME | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18147251 | REFINING METHOD | Final Rejection | NGK Insulators, Ltd. |
| 18514387 | COMPOSITION FOR IMPROVING COGNITIVE FUNCTION, AGENT FOR IMPROVING COGNITIVE FUNCTION, AND FOOD FOR IMPROVING COGNITIVE FUNCTION | Non-Final OA | AJINOMOTO CO., INC. |
| 18173386 | NUCLEIC ACID EXTRACTION AND AMPLIFICATION CONTROLS AND METHODS OF USE THEREOF | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 17787952 | WATER-SOLUBLE CONJUGATED POLYMER FOR PHOTOTHERMAL THERAPY, POLYMERIZED MONOMER THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Final Rejection | SOUTH CHINA UNIVERSITY OF TECHNOLOGY |
| 18256647 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | Final Rejection | BAYER AKTIENGESELLSCHAFT |
| 18735600 | OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE | Non-Final OA | PanOptica, Inc. |
| 17890782 | DIAGNOSTIC METHODS FOR INFLAMMATORY DISORDERS | Final Rejection | Meso Scale Technologies, LLC. |
| 18553769 | CEFTIBUTEN DOSING REGIMENS | Non-Final OA | QPEX Biopharma, Inc. |
| 18340824 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | Non-Final OA | Oxford Nanopore Technologies PLC |
| 17996302 | INHIBITION OF BAX-MEDIATED CELL DEATH BY ELTROMBOPAG | Final Rejection | Albert Einstein College of Medicine |
| 18560316 | 6-HYDROXY-CANNABIDIOL-C4 | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 17430557 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST | Non-Final OA | KAGOSHIMA UNIVERSITY |
| 14407174 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | Final Rejection | Takeda Pharmaceutical Company Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy